Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis
Ημερομηνία
2010Συγγραφέας
![ORCID logo](https://orcid.org/sites/default/files/images/orcid_16x16.png)
![ORCID logo](https://orcid.org/sites/default/files/images/orcid_16x16.png)
![ORCID logo](https://orcid.org/sites/default/files/images/orcid_16x16.png)
Griva, Theodora
Anagnostis, Panagiotis
Kargiotis, Konstantinos
![ORCID logo](https://orcid.org/sites/default/files/images/orcid_16x16.png)
![ORCID logo](https://orcid.org/sites/default/files/images/orcid_16x16.png)
Karagiannis, Asterios
Mikhailidis, Dimitri P.
Basdekas, S.
Bouloukos, V.
![ORCID logo](https://orcid.org/sites/default/files/images/orcid_16x16.png)
Dimopoulou, S.
Hartamba, E.
Kakafika, A.
Kapousouzi, M.
Koumaras, H.
Mitsiou, E.
Papageorgiou, A.
Pehlivanidis, A.
Petridis, D.
Sekeri, Z.
Skaperdas, A.
Symeonidis, A.
Source
The LancetVolume
376Issue
9756Pages
1916-22Google Scholar check
Keyword(s):
Metadata
Εμφάνιση πλήρους εγγραφήςΕπιτομή
Long-term statin treatment reduces the frequency of cardiovascular events, but safety and efficacy in patients with abnormal liver tests is unclear. We assessed whether statin therapy is safe and effective for these patients through post-hoc analysis of the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) study population. GREACE was a prospective, intention-to-treat study that randomly assigned by a computer-generated randomisation list 1600 patients with coronary heart disease (aged 2.6 mmol/L and triglycerides <4.5 mmol/L) at the Hippokration University Hospital, Thessaloniki, Greece to receive statin or usual care, which could include statins. The primary outcome of our post-hoc analysis was risk reduction for first recurrent cardiovascular event in patients treated with a statin who had moderately abnormal liver tests (defined as serum alanine aminotransferase or aspartate aminotransferase concentrations of less than three times the upper limit of normal) compared with patients with abnormal liver tests who did not receive a statin. This risk reduction was compared with that for patients treated (or not) with statin and normal liver tests. Of 437 patients with moderately abnormal liver tests at baseline, which were possibly associated with non-alcoholic fatty liver disease, 227 who were treated with a statin (mainly atorvastatin 24 mg per day) had substantial improvement in liver tests (p<0.0001) whereas 210 not treated with a statin had further increases of liver enzyme concentrations. Cardiovascular events occurred in 22 (10%) of 227 patients with abnormal liver tests who received statin (3.2 events per 100 patient-years) and 63 (30%) of 210 patients with abnormal liver tests who did not receive statin (10.0 events per 100 patient-years; 68% relative risk reduction, p<0.0001). This cardiovascular disease benefit was greater (p=0.0074) than it was in patients with normal liver tests (90 [14%] events in 653 patients receiving a statin [4.6 per 100 patient-years] vs 117 [23%] in 510 patients not receiving a statin [7.6 per 100 patient-years]; 39% relative risk reduction, p<0.0001). Seven (<1%) of 880 participants who received a statin discontinued statin treatment because of liver-related adverse effects (transaminase concentrations more than three-times the upper limit of normal). Statin treatment is safe and can improve liver tests and reduce cardiovascular morbidity in patients with mild-to-moderately abnormal liver tests that are potentially attributable to non-alcoholic fatty liver disease. None.
Collections
Cite as
Related items
Showing items related by title, author, creator and subject.
-
Article
Systemic treatment-induced gastrointestinal toxicity: Incidence, clinical presentation and management
Boussios, Stergios; Pentheroudakis, George; Katsanos, K.; Pavlidis, Nicholas (2012)The toxicity of cancer chemotherapy is among the most important factors limiting its use. Clear delineation and communication of benefits and risks is an essential component of treatment decisions. Gastrointestinal toxicity ...
-
Article
«Juvenile» oncology - A missing subspecialty. The experience of a reference cancer centre
Pentheroudakis, George; Mauri, D.; Kostadima, Lida; Golfinopoulos, Vassilis; Alexiou, G.; Karakatsanis, A.; Pavlidis, Nicholas (2006)Introduction: Despite unique tumor epidemiology and a higher cancer incidence compared to pediatric patients, adolescents and young adults have not been receiving specialized, multidisciplinary, centralized care. In an ...
-
Article
Multicenter phase-II trial of irinotecan plus oxaliplatin [IROX regimen] in patients with poor-prognosis cancer of unknown primary: A hellenic cooperative oncology group study
Briassoulis, E. Ch; Fountzilas, George; Bamias, A. T.; Dimopoulos, M. A.; Xiros, N.; Aravantinos, Gerasimos; Samantas, E.; Kalofonos, H. P.; Makatsoris, T.; Mylonakis, N.; Papakostas, P.; Skarlos, Dimosthenis V.; Varthalitis, I.; Pavlidis, Nicholas (2008)Background: Cancer of unknown primary (CUP) lacks established therapy although it affects 3% of cancer patients. We evaluated the irinotecan- oxaliplatin combination (IROX regimen) in previously untreated patients with ...